High Burden of Deep-Seated Plexiform Neurofibromas (PN) in Children with Neurofibromatosis 1 (NF1): Image-Defined Risk Factors

被引：0
|
作者：
Kelaidi, C. [1 ]
Petrikkos, L. [1 ]
Tzotzola, V. S. [1 ]
Antoniadi, K. [1 ]
Gavra, M. [2 ]
Stefanaki, K. [3 ]
Polychronopoulou, S. [1 ]
机构：
[1] Aghia Sophia Childrens Hosp, Dept Pediat Hematol & Oncol, Athens, Greece
[2] Aghia Sophia Childrens Hosp, Dept Radiol, Athens, Greece
[3] Aghia Sophia Childrens Hosp, Dept Pathol, Athens, Greece
来源：
PEDIATRIC BLOOD & CANCER | 2019年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V395 SIOP1
引用
下载
收藏
页码：S355 / S355
页数：1
相关论文
共 50 条
  • [41] Quantitative analysis of NF1 and OMGP gene transcripts in sporadic gliomas, sporadic meningiomas and neurofibromatosis type 1-associated plexiform neurofibromas
    Nils Peters
    Andreas Waha
    Ruth Wellenreuther
    Reinhard E. Friedrich
    Victor F. Mautner
    Sven Hoffmeyer
    Doris Lenartz
    Johannes Schramm
    Otmar D. Wiestler
    Andreas von Deimling
    Acta Neuropathologica, 1999, 97 : 547 - 551
  • [42] Phase II trial of the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886 Hydrogen Sulfate) in adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN).
    Coyne, Geraldine Helen O'Sullivan
    Gross, Andrea M.
    Dombi, Eva
    Tibery, Cecilia
    Carbonell, Amanda
    Takebe, Naoko
    Derdak, Joanne
    Pichard, Dominique
    Srivastava, Apurva K.
    Herrick, William
    Parchment, Ralph E.
    Martin, Staci
    Wolters, Pamela
    Whitcomb, Patricia
    Rubinstein, Lawrence
    Doroshow, James H.
    Chen, Alice P.
    Widemann, Brigitte C.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [43] Phase II Trial of the MEK 1/2 inhibitor selumetinib (AZD6344, ARRY-142886 hydrogen sulphate) in adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN)
    Coyne, Geraldine O'Sullivan
    Gross, Andrea
    Dombi, Eva
    DeSanto, Jennifer
    Carbonell, Amanda
    Derdak, Joanne
    Pichard, Dominique
    Wood, Brad
    Tibery, Cecilia
    Wolters, Pam
    Whitcomb, Trish
    Martin, Staci
    Bradford, Diana
    Srivastava, Apurva
    Herrick, William
    Parchment, Ralph
    Heisey, Kara
    Doyle, Austin
    Takebe, Naoko
    Doroshow, James H.
    Chen, Alice P.
    Widemann, Brigitte
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
  • [44] Tumor burden evaluation in NF1 patients with plexiform neurofibromas in daily clinical practice (vol 157, pg 855, 2015)
    Pratt, L.
    Helfer, D.
    Weizman, L.
    Shofty, B.
    Constantini, S.
    Joskowicz, L.
    Ben Bashat, D.
    Ben-Sira, L.
    ACTA NEUROCHIRURGICA, 2015, 157 (06) : 1091 - 1091
  • [45] Analysis of NF1 somatic mutations in cutaneous neurofibromas from patients with high tumor burden
    Laura Thomas
    Lan Kluwe
    Nadia Chuzhanova
    Victor Mautner
    Meena Upadhyaya
    neurogenetics, 2010, 11 : 391 - 400
  • [46] Analysis of NF1 somatic mutations in cutaneous neurofibromas from patients with high tumor burden
    Thomas, Laura
    Kluwe, Lan
    Chuzhanova, Nadia
    Mautner, Victor
    Upadhyaya, Meena
    NEUROGENETICS, 2010, 11 (04) : 391 - 400
  • [47] OBSERVATIONAL REGISTRY STUDY OF TREATMENT PRACTICES AND LONG-TERM OUTCOMES OF CHILDREN WITH NEUROFIBROMATOSIS TYPE 1 (NF1) AND PLEXIFORM NEUROFIBROMAS (PN) INITIATING SELUMETINIB IN REALWORLD PRACTICE IN THE UNITED STATES (US): STUDY DESIGN AND METHODOLOGY
    Waanders, Angela
    Yohay, Kaleb
    Fang, Shona
    Wahlstrom, Svea
    Bornhorst, Miriam
    Meade, Julia
    Vallance, Kelly
    Rodriguez, Randolph de la Rosa
    NEURO-ONCOLOGY, 2023, 25
  • [48] ReNeu: A pivotal phase 2b trial of mirdametinib in children and adults with neurofibromatosis type 1 (NF1)-associated symptomatic inoperable plexiform neurofibroma (PN).
    Moertel, Christopher L.
    Hirbe, Angela C.
    Shuhaiber, Hans H.
    Viskochil, David
    Sidhu, Alpa
    Bielamowicz, Kevin J.
    Weber, Michael
    Li, Jack
    Smith, L. Mary
    Weintraub, Lauren
    McNall-Knapp, Rene Y.
    Hajjar, Fouad M.
    Foreman, Nicholas K.
    Gershon, Timothy R.
    Babovic-Vuksanovic, Dusica
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [49] SELUMETINIB (AZD6244) HYDROGEN SULFATE, A MEK1/2 INHIBITOR, IN CHILDREN WITH NEUROFIBROMATOSIS TYPE 1 (NF1) AND INOPERABLE PLEXIFORM NEUROFIBROMAS (PNS): A PHASE I STUDY
    Fisher, Michael J.
    Marcus, Leigh
    Weiss, Brian
    Kim, AeRang
    Dombi, Eva
    Baldwin, Andrea
    Whitcomb, Patricia
    Martin, Staci
    Gillespie, Andrea
    Doyle, Austin
    Widemann, Brigitte C.
    NEURO-ONCOLOGY, 2014, 16 : 129 - 129
  • [50] Phase 1 study of the MEK1/2 inhibitor selumetinib (AZD6244) hydrogen sulfate in children and young adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PNs).
    Widemann, Brigitte C.
    Marcus, Leigh Jessica
    Fisher, Michael J.
    Weiss, Brian D.
    Kim, AeRang
    Dombi, Eva
    Baldwin, Andrea
    Whitcomb, Patricia
    Martin, Staci
    Gillespie, Andrea
    Doyle, Austin
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345